Bone disease in eliglustat treated Gaucher disease type 1 patients: A real-world experience in a tertiary referral hospital

被引：0
|
作者：
Valls-Villalba, Angel [1 ]
Camprodon-Gomez, Maria [2 ]
Moreno-Martinez, Daniel [3 ]
Hernandez-Vara, Jorge [4 ]
Arranz-Amo, Jose Antonio [5 ]
Carnicer-Caceres, Clara [5 ]
机构：
[1] Vall Hebron Univ Hosp, Internal Med, Barcelona, Spain
[2] Vall DHebron Univ Hosp, Unit Rare Dis & Metab Hereditary Disorders, Barcelona, Spain
[3] Vall Hebron Univ Hosp, Dept Radiol, Barcelona, Spain
[4] Vall Hebron Univ Hosp, Dept Neurol, Unit Movement Disorders, Barcelona, Spain
[5] Vall Hebron Univ Hosp, Inborn Error Metab Lab, Barcelona, Spain
来源：
MOLECULAR GENETICS AND METABOLISM | 2023年 / 138卷 / 02期
关键词：
D O I：
10.1016/j.ymgme.2022.107340
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
357
引用
收藏
页码：129 / 129
页数：1
相关论文
共 50 条
  • [21] Transition to eliglustat in an individual with Gaucher disease type 1 on antipsychotic medication
    Ortiz, Damara
    Barch, Joshua
    Segady, Kayla
    Henderson, Nadene
    [J]. MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S80 - S80
  • [22] Clinical potential of eliglustat tartrate in the treatment of type 1 Gaucher disease
    Kaplan, Paige
    [J]. RESEARCH AND REPORTS IN ENDOCRINE DISORDERS, 2014, 4
  • [23] Upadacitinib: A real-world tertiary Australian hospital experience
    Yogakanthi, S.
    Hartley, I.
    Ding, J. N.
    Schulberg, J.
    Connell, W.
    Kamm, M. A.
    Basnayake, C.
    Lust, M.
    Niewiadomski, O.
    Wright, E.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 152 - 152
  • [24] Age-specific risk of Parkinson disease and Parkinsonian syndrome in patients with Gaucher disease type 1: Real-world evidence from the International Collaborative Gaucher Group Gaucher Registry
    Balwani, Manisha
    Mistry, Pramod K.
    di Fonzo, Alessio Barnaba
    Batista, Julie
    Bianculli, Pablo
    Carwile, Jenny L.
    Perichon, Maria
    Alcalay, Roy
    [J]. MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
  • [25] Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat
    Ravi S. Kamath
    Elena Lukina
    Nora Watman
    Marta Dragosky
    Gregory M. Pastores
    Elsa Avila Arreguin
    Hanna Rosenbaum
    Ari Zimran
    Rasha Aguzzi
    Ana Cristina Puga
    Andrea M. Norfleet
    M. Judith Peterschmitt
    Daniel I. Rosenthal
    [J]. Skeletal Radiology, 2014, 43 : 1353 - 1360
  • [26] Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat
    Kamath, Ravi S.
    Lukina, Elena
    Watman, Nora
    Dragosky, Marta
    Pastores, Gregory M.
    Avila Arreguin, Elsa
    Rosenbaum, Hanna
    Zimran, Ari
    Aguzzi, Rasha
    Puga, Ana Cristina
    Norfleet, Andrea M.
    Peterschmitt, M. Judith
    Rosenthal, Daniel I.
    [J]. SKELETAL RADIOLOGY, 2014, 43 (10) : 1353 - 1360
  • [27] Two-year postmarketing safety experience with oral eliglustat in adults with type 1 Gaucher disease
    Hou, Audrey W.
    Patel, Palni
    Peterschmitt, M. Judith
    Ibrahim, Jennifer
    Gaemers, Sebastiaan J. M.
    [J]. MOLECULAR GENETICS AND METABOLISM, 2017, 120 (1-2) : S67 - S67
  • [28] Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project
    Giraldo, Pilar
    Alfonso, Pilar
    Atutxa, Koldo
    Fernandez-Galan, Maria A.
    Barez, Abelardo
    Franco, Rafael
    Alonso, Dora
    Martin, Alejandro
    Latre, Paz
    Pocovi, Miguel
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (12): : 1771 - 1775
  • [29] Type 1 Gaucher disease (CYP2D6-eliglustat)
    Becquemont, Laurent
    [J]. THERAPIE, 2017, 72 (02): : 323 - 326
  • [30] Real-World Experience of Ustekinumab in Crohn's Disease Patients With Prior Anti-TNF Therapy at a Tertiary Care Hospital
    Kartikeya, Tripathi
    Kevin, Groudan
    Jean, Chalhoub
    Arushika, Yedla
    Rohit, Singhania
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S17 - S17
12345